Cargando…
Experiences and Treatment Preferences in Patients With Psoriatic Arthritis: A Cross-Sectional Study in the ArthritisPower Registry
INTRODUCTION: Despite recent advances in treatment for psoriatic arthritis (PsA), many patients experience inadequate response or intolerance to therapy, indicating that unmet treatment-related needs remain. To further characterize these unmet needs, we evaluated patients’ experiences regarding the...
Autores principales: | Ogdie, Alexis, Myers, Kelley, Mansfield, Carol, Tillett, William, Nash, Peter, Leach, Colton, Nowell, W. Benjamin, Gavigan, Kelly, Zueger, Patrick, McDearmon-Blondell, Erin, Walsh, Jessica |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8964868/ https://www.ncbi.nlm.nih.gov/pubmed/35279798 http://dx.doi.org/10.1007/s40744-022-00436-x |
Ejemplares similares
-
Correction: Experiences and Treatment Preferences in Patients With Psoriatic Arthritis: A Cross-Sectional Study in the ArthritisPower Registry
por: Ogdie, Alexis, et al.
Publicado: (2022) -
Barriers to treatment optimization and achievement of patients’ goals: perspectives from people living with rheumatoid arthritis enrolled in the ArthritisPower registry
por: Gavigan, Kelly, et al.
Publicado: (2020) -
Patient-Reported Nausea and Fatigue Related to Methotrexate: A Prospective, Self-Controlled Study in the ArthritisPower(®) Registry
por: Nowell, W. Benjamin, et al.
Publicado: (2021) -
Improvement in Patient-Reported Outcomes in Patients with Psoriatic Arthritis Treated with Upadacitinib Versus Placebo or Adalimumab: Results from SELECT-PsA 1
por: Strand, Vibeke, et al.
Publicado: (2021) -
Upadacitinib as monotherapy and in combination with non-biologic disease-modifying antirheumatic drugs for psoriatic arthritis
por: Nash, Peter, et al.
Publicado: (2021)